TREM1 and Sepsis: After some promising results concerning sepsis treatment in mice with LR17 [22, 77], it turned out that just 12 amino acids accounted for LR17’s anti-inflammatory effects, and a new peptide containing this sequence (LQEEDAGEYGCM) was designed [9, 12, 22] and is the first TREM-1 inhibitor that has been tested in clinical trials.